Holen Sie sich die Stockscreener-App
5.84
3.10%
0.20
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Support Zone Holds Steady for Recursion Pharmaceuticals Inc. After DipJuly 2025 Macro Moves & Trade Opportunity Analysis Reports - 선데이타임즈
Recursion Pharmaceuticals Insider Sold Shares Worth $3,263,964, According to a Recent SEC Filing - MarketScreener
Recursion Pharma CEO Gibson sells shares worth $3.26 million By Investing.com - Investing.com South Africa
Recursion Pharma CEO Gibson sells shares worth $3.26 million - Investing.com
Is Recursion On A Breakthrough Path? - timothysykes.com
Recursion Pharmaceuticals: Two Clinical Readouts In H2'25 (NASDAQ:RXRX) - Seeking Alpha
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Recursion Bets Big On AI-Driven Drug Discovery, But Losses Mount - Finimize
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - Mitrade
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - 富途牛牛
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Recursion Pharmaceuticals and Biodexa: A High-Stakes Race in the FAP Market - AInvest
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards? - MSN
Recursion Pharmaceuticals: Strong Financial Position and Strategic Focus Justify Buy Rating - TipRanks
Recursion's Q2 2025 Earnings Call: Unpacking Key Contradictions in Strategy and Innovation - AInvest
Recursion Pharmaceuticals (RXRX): A Deep Dive into Platform-Driven Value Creation and Strategic Milestone Potential in 2025 - AInvest
Recursion Pharmaceuticals sets $100M partnership inflows target by 2026, extends cash runway to Q4 2027 - AInvest
Pharma Boom: RXRX Stocks Soar After Latest Innovation - timothysykes.com
Recursion Pharmaceuticals (RXRX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Wider-Than-Expected Q2 Loss, Beats Revenue Estimates - Benzinga
Recursion Pharmaceuticals reports Q2 EPS (41c), consensus (35c) - TipRanks
Earnings call transcript: Recursion Pharmaceuticals Q2 2025 sees revenue beat - Investing.com
Recursion Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Up 50% in 3 Months, Is This Stock Still a Buy? - AOL.com
Recursion Pharmaceuticals Fiscal Q2 Loss Widens, Revenue Rises - MarketScreener
Recursion Pharmaceuticals shares rise 4.31% premarket after reporting revenue of $19.2 million, exceeding expectations. - AInvest
Why Recursion Pharmaceuticals Shares Are Gaining Momentum - TipRanks
Recursion Pharmaceuticals earnings missed by $0.06, revenue topped estimates - Investing.com Australia
RECURSION PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
0.07%
0.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):